Skip to content

Schrodinger

US · SDGR #2667 by market cap Listed 2020
27.29 -1.61 -5.57%
Live - 5344 symbols - heartbeat 30s ago · 2026-10-08 06:53
Pre-market 26.80 -1.80%
After-hours 27.20 -0.33%
Overnight 27.29 0.00%
Market cap
2.04B
P/B
6.21
EPS
-1.41
Reader sentiment Are you bullish or bearish on SDGR?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 6.57 Expensive vs history 98th percentile
5-year average 3.84 · #34 of 41 in Health Information Services
P/E ratio -39.59 Cheap vs history 3rd percentile
5-year average 10.98 · forward -14.34
P/S ratio 8.35 In line with history 45th percentile
5-year average 9.97 · forward 9.12 · #34 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Schrodinger (SDGR) 2.04B -37.38 6.21 0.00%
Veeva Systems (VEEV) 45.74B 46.31 6.15 0.00%
Tempus AI (TEM) 12.69B -48.85 28.53 0.00%
BrightSpring Health Services (BTSG) 12.62B 38.67 6.16 0.00%
Hinge Health (HNGE) 7.90B 73.14 22.93 0.00%
HealthEquity (HQY) 7.60B 33.18 3.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value47.50 Economic moatNone UncertaintyVery High

Trading 74.1% below Morningstar's fair value estimate.

Fair value

Schrodinger Inc earns a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 31% discount to our quantitative fair value estimate of $47.50 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity bolsters our fair value estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days falls in the top 30% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -4.2%, a core component of profitability, lies in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 06:53:52 · For reference only, not investment advice and not tailored to your situation.